Commenting on the preliminary results of the trial, Dr. Wurster said, “This is the largest series to date that examines how dabigatran is being administered in real-world settings, and I think our findings illustrate some areas of concern with respect to new agents for anticoagulation therapy. This is not to say that our results indicate that dabigatran is not a good medicine, but we need more information regarding appropriate patient selection and monitoring. As the study progresses, we hope to be able to answer some of these questions.”The “Dabigatran in the Real World” study remains active, and the final report will include information on possible contributing factors like renal function, co-morbid conditions, and concomitant medication use. Meanwhile, results of the study to date support the conclusion that warfarin remains an affordable, effective, and safe option for many patients. Dr. Wurster will be hosting a webinar to discuss these findings on Wednesday, May 23 rd at 3:00 PM ET. Click here to register.
Preliminary Results Of Prospective Trial Suggest Warfarin May Be A Safer Option For Patients Than Alternative Therapies
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts